

**Appendix A: Claims As Amended in Amendment After Allowance**

Claims 1-34. (Canceled)

35. (Previously presented) A method for reducing food intake in a subject desirous or in need of reducing food intake, comprising peripherally administering to said subject an amount of an exendin effective to reduce food intake.

36. (Previously presented) The method according to claim 35, wherein said peripheral administration is by injection.

37. (Previously presented) The method according to claim 35, wherein said peripheral administration is selected from the group consisting of intravenous administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, oral administration, topical administration, transmucosal administration, and pulmonary administration.

38. (Previously presented) The method according to claim 35, wherein about 10 µg/70 kg to about 5 mg/70 kg of the exendin is administered per day in single or divided doses.

39. (Previously presented) The method according to claim 35, wherein about 10 µg/70 kg to about 2 mg/70 kg of the exendin is administered per day in single or divided doses.

40. (Previously presented) The method according to claim 35, wherein about 10 µg/70 kg to about 500 µg/70 kg of the exendin is administered per day in single or divided doses.

41. (Previously presented) The method according to claim 35, wherein about 0.1 µg/kg to about 100 µg/kg of the exendin is administered per day in single or divided doses.

42. (Previously presented) The method according to claim 35, wherein about 0.1 µg/kg to about 10 µg/kg of the exendin is administered per day in single or divided doses.

43. (Previously presented) The method according to claim 35, wherein about 0.1 µg/kg to about 1 µg/kg of the exendin is administered per day in single or divided doses.

44. (Previously presented) The method of claim 35, wherein said subject is human.

45. (Previously presented) The method of claim 35, wherein said subject suffers from Type II diabetes.

46. (Previously presented) The method of claim 35, wherein said subject suffers from an eating disorder.

47. (Previously presented) The method of claim 35, wherein said subject suffers from an insulin-resistance syndrome.

48. (Previously presented) The method of claim 35, wherein said exendin is exendin-3.

49. (Previously presented) The method of claim 35, wherein said exendin is exendin-4.

50. (Previously presented) The method of claim 35, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a cholecystokinin (CCK).

51. (Previously presented) A method for reducing appetite in a subject desirous or in need of reducing appetite, comprising peripherally administering to said subject an amount of an exendin effective to reduce appetite.

52. (Previously presented) The method according to claim 51, wherein said peripheral administration is by injection.

53. (Previously presented) The method according to claim 51, wherein said peripheral administration is selected from the group consisting of intravenous administration, intraperitoneal administration, subcutaneous administration,

intramuscular administration, oral administration, topical administration, transmucosal administration, and pulmonary administration.

54. (Previously presented) The method according to claim 51, wherein about 10 µg/70 kg to about 5 mg/70 kg of the exendin is administered per day in single or divided doses.

55. (Previously presented) The method according to claim 51, wherein about 10 µg/70 kg to about 2 mg/70 kg of the exendin is administered per day in single or divided doses.

56. (Previously presented) The method according to claim 51, wherein about 10 µg/70 kg to about 500 µg/70 kg of the exendin is administered per day in single or divided doses.

57. (Previously presented) The method according to claim 51, wherein about 0.1 µg/kg to about 100 µg/kg of the exendin is administered per day in single or divided doses.

58. (Previously presented) The method according to claim 51, wherein about 0.1 µg/kg to about 10 µg/kg of the exendin is administered per day in single or divided doses.

59. (Previously presented) The method according to claim 51, wherein about 0.1 µg/kg to about 1 µg/kg of the exendin is administered per day in single or divided doses.

60. (Previously presented) The method of claim 51, wherein said subject is human.

61. (Previously presented) The method of claim 51, wherein said subject suffers from Type II diabetes.

62. (Previously presented) The method of claim 51, wherein said subject suffers from an eating disorder.

63. (Previously presented) The method of claim 51, wherein said subject suffers from an insulin-resistance syndrome.

64. (Previously presented) The method of claim 51, wherein said exendin is exendin-3.

65. (Previously presented) The method of claim 51, wherein said exendin is exendin-4.

66. (Previously presented) The method of claim 51, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a cholecystokinin (CCK).

Claims 67-72. (Cancelled).

73. (Previously Presented) A method for reducing food intake in a subject desirous or in need of reducing food intake, comprising peripherally administering to said subject an amount of exendin-4 effective to reduce food intake.

74. (Previously presented) The method according to claim 73, wherein said peripheral administration is by injection.

75. (Previously presented) The method according to claim 73, wherein said peripheral administration is selected from the group consisting of intravenous administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, oral administration, topical administration, transmucosal administration, and pulmonary administration.

76. (Previously presented) The method according to claim 73, wherein about 10  $\mu$ g/70 kg to about 5 mg/70 kg of the exendin-4 is administered per day in single or divided doses.

77. (Previously presented) The method according to claim 73, wherein about 10  $\mu$ g/70 kg to about 2 mg/70 kg of the exendin-4 is administered per day in single or divided doses.

78. (Previously presented) The method according to claim 73, wherein about 10 µg/70 kg to about 500 µg/70 kg of the exendin-4 is administered per day in single or divided doses.

79. (Previously presented) The method according to claim 73, wherein about 0.1 µg/kg to about 100 µg/kg of the exendin-4 is administered per day in single or divided doses.

80. (Previously presented) The method according to claim 73, wherein about 0.1 µg/kg to about 10 µg/kg of the exendin-4 is administered per day in single or divided doses.

81. (Previously presented) The method according to claim 73, wherein about 0.1 µg/kg to about 1 µg/kg of the exendin-4 is administered per day in single or divided doses.

82. (Previously presented) The method of claim 73, wherein said subject is human.

83. (Previously presented) The method of claim 73, wherein said subject suffers from Type II diabetes.

84. (Previously presented) The method of claim 73, wherein said subject suffers from an eating disorder.

85. (Previously presented) The method of claim 73, wherein said subject suffers from an insulin-resistance syndrome.

86. (Previously presented) The method of claim 73, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a cholecystokinin (CCK).

87. (Previously presented) A method for reducing appetite in a subject desirous or in need of reducing appetite, comprising peripherally administering to said subject an amount of exendin-4 effective to reduce appetite.

88. (Previously presented) The method according to claim 87, wherein said peripheral administration is by injection.

89. (Previously presented) The method according to claim 87, wherein said peripheral administration is selected from the group consisting of intravenous administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, oral administration, topical administration, transmucosal administration, and pulmonary administration.

90. (Previously presented) The method according to claim 87, wherein about 10 µg/70 kg to about 5 mg/70 kg of the exendin-4 is administered per day in single or divided doses.

91. (Previously presented) The method according to claim 87, wherein about 10 µg/70 kg to about 2 mg/70 kg of the exendin-4 is administered per day in single or divided doses.

92. (Previously presented) The method according to claim 87, wherein about 10 µg/70 kg to about 500 µg/70 kg of the exendin-4 is administered per day in single or divided doses.

93. (Previously presented) The method according to claim 87, wherein about 0.1 µg/kg to about 100 µg/kg of the exendin-4 is administered per day in single or divided doses.

94. (Previously presented) The method according to claim 87, wherein about 0.1 µg/kg to about 10 µg/kg of the exendin-4 is administered per day in single or divided doses.

95. (Previously presented) The method according to claim 87, wherein about 0.1 µg/kg to about 1 µg/kg of the exendin-4 is administered per day in single or divided doses.

96. (Previously presented) The method of claim 87, wherein said subject is human.

97. (Previously presented) The method of claim 87, wherein said subject suffers from Type II diabetes.

98. (Previously presented) The method of claim 87, wherein said subject suffers from an eating disorder.

99. (Previously presented) The method of claim 87, wherein said subject suffers from an insulin-resistance syndrome.

100. (Previously presented) The method of claim 87, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a cholecystokinin (CCK).

Claims 101-112. (Cancelled)